359 filings
Page 2 of 18
6-K
wb434s tx
11 Oct 23
Report of Foreign Private Issuer
7:00am
6-K
h2i40ryuwb
26 Sep 23
Report of Foreign Private Issuer
7:00am
6-K
xmz8lnk
8 Sep 23
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
7:00am
6-K
9taj6
6 Sep 23
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
7:00am
424B5
dnbreow9acy 8yoo
1 Sep 23
Prospectus supplement for primary offering
5:16pm
6-K
r134rgbu0u
1 Sep 23
Report of Foreign Private Issuer
4:46pm
6-K
k1y4j3
23 Aug 23
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
10:30am
6-K
cqz2620bn
23 Aug 23
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
7:00am
6-K
ieue55q5f5x84u
17 Aug 23
Report of Foreign Private Issuer
7:00am
6-K
27gghnszeghsgke37
15 Aug 23
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
7:00am
6-K
oorord h3k
21 Jul 23
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
4:15pm
20-F/A
tdrq2 zy29z50s6z26w
13 Jun 23
Annual report (foreign) (amended)
12:37pm
6-K
lcw961dz
13 Jun 23
Report of Foreign Private Issuer
7:00am
6-K
mtlw0n
5 Jun 23
Report of Foreign Private Issuer
10:29am
6-K
proi78pm2qkx
25 May 23
Report of Foreign Private Issuer
7:01am
6-K
q9gxjm
23 May 23
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
7:00am
6-K
ckeq7gdzimo7g7 qg
17 May 23
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
7:00am
6-K
ghjsrpy v5ff
27 Apr 23
Report of Foreign Private Issuer
7:02am
6-K
hbs2p6knvm836sliskce
26 Apr 23
Report of Foreign Private Issuer
2:52pm